Search

Your search keyword '"Pavletic, Steven Z."' showing total 922 results
Start Over Author "Pavletic, Steven Z." Search Limiters Available in Library Collection
922 results on '"Pavletic, Steven Z."'

1. High-dose alemtuzumab and cyclosporine vs tacrolimus, methotrexate, and sirolimus for chronic graft-versus-host disease prevention

Author

Holtzman, Noa G., Curtis, Lauren M., Salit, Rachel B., Shaffer, Brian C., Pirsl, Filip, Ostojic, Alen, Steinberg, Seth M., Schulz, Eduard, Wilder, Jennifer S., Hughes, Thomas E., Rose, Jeremy, Memon, Sarfraz, Korngold, Robert, Gea-Banacloche, Juan C., Fowler, Daniel H., Hakim, Frances T., Gress, Ronald E., Bishop, Michael R., and Pavletic, Steven Z.

Published
2024
Full Text
View/download PDF

3. Heightened TLR7 signaling primes BCR-activated B cells in chronic graft-versus-host disease for effector functions

Author

Bracken, Sonali J., Suthers, Amy N., DiCioccio, Rachel A., Su, Hsuan, Anand, Sarah, Poe, Jonathan C., Jia, Wei, Visentin, Jonathan, Basher, Fahmin, Jordan, Collin Z., McManigle, William C., Li, Zhiguo, Hakim, Frances T., Pavletic, Steven Z., Bhuiya, Nazmim S., Ho, Vincent T., Horwitz, Mitchell E., Chao, Nelson J., and Sarantopoulos, Stefanie

Published
2024
Full Text
View/download PDF

6. Motor ability, function, and health-related quality of life as correlates of symptom burden in patients with sclerotic chronic graft-versus-host disease receiving imatinib mesylate.

Author

Rosenthal, Emily A, Ho, Pei-Shu, Joe, Galen O, Mitchell, Sandra A, Booher, Susan, Pavletic, Steven Z, Baird, Kristin, Cowen, Edward W, and Comis, Leora E

Subjects
Humans, Graft vs Host Disease, Chronic Disease, Sclerosis, Motor Skills, Quality of Life, Adolescent, Adult, Middle Aged, Child, Female, Male, Clinical Trials, Phase II as Topic, Young Adult, Imatinib Mesylate, Allogeneic hematopoietic stem cell transplantation, Chronic graft-versus-host disease, Functional impairment, Health-related quality of life, Symptom burden, Brain Disorders, Physical Rehabilitation, Rehabilitation, Clinical Trials and Supportive Activities, Clinical Research, Good Health and Well Being, Medical and Health Sciences, Psychology and Cognitive Sciences, Oncology & Carcinogenesis
Abstract

PurposeTo explore improvement in motor ability, function, health-related quality of life (HRQOL), and symptom severity in patients with sclerotic chronic graft-versus-host disease (ScGVHD) in response to treatment as well as the relationship among changes on such measures.MethodsThis study was a secondary analysis of data from 13 individuals with severe ScGVHD enrolled in a clinical trial evaluating the efficacy of imatinib mesylate (clinicaltrials.gov identifier: NCT00702689). Self-reported, clinician-reported, and performance-based indicators of motor ability, function, HRQOL, and symptom severity were assessed at baseline and 6 months following the administration of imatinib mesylate.ResultsParticipants did not show statistically significant improvement on any measures over time. Approximately one-third of patients displayed clinically significant improvement on measures of motor ability (palmar pinch strength, dominant hand, 30.8%), functioning (Manual Ability Measure-36, 41.7%), HRQOL (Short Form 36 [SF-36] Mental Component Summary, 33.3%), and symptom severity (Lee Symptom Scale, 38.5%). Improvement in cGVHD symptom burden was correlated with improvement in function (Assessment of Motor and Process Skills [AMPS] and Disabilities of the Arm, Shoulder, and Hand [DASH] scores) and HRQOL (SF-36 Physical Component Summary scores).ConclusionsFindings suggest the potential utility of administering patient-reported and performance-based functional measures, such as the DASH and the AMPS, to patients with cGVHD. By understanding the functional consequences of ScGVHD, interdisciplinary teams of health care providers, including rehabilitation professionals, can work to improve long-term outcomes.

Published
2020

7. Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)

Author

Kansagra, Ankit J, Frey, Noelle V, Bar, Merav, Laetsch, Theodore W, Carpenter, Paul A, Savani, Bipin N, Heslop, Helen E, Bollard, Catherine M, Komanduri, Krishna V, Gastineau, Dennis A, Chabannon, Christian, Perales, Miguel A, Hudecek, Michael, Aljurf, Mahmoud, Andritsos, Leslie, Barrett, John A, Bachanova, Veronika, Bonini, Chiara, Ghobadi, Armin, Gill, Saar I, Hill, Joshua A, Kenderian, Saad, Kebriaei, Partow, Nagler, Arnon, Maloney, David, Liu, Hien D, Shah, Nirali N, Kharfan-Dabaja, Mohamed A, Shpall, Elizabeth J, Mufti, Ghulam J, Johnston, Laura, Jacoby, Elad, Bazarbachi, Ali, DiPersio, John F, Pavletic, Steven Z, Porter, David L, Grupp, Stephan A, Sadelain, Michel, Litzow, Mark R, Mohty, Mohamad, and Hashmi, Shahrukh K

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Cancer, Pediatric, Childhood Leukemia, Immunization, Genetics, Transplantation, Biotechnology, Gene Therapy, Pediatric Cancer, Pediatric Research Initiative, Hematology, Orphan Drug, Rare Diseases, Development of treatments and therapeutic interventions, 5.2 Cellular and gene therapies, Good Health and Well Being, Clinical Sciences, Cardiovascular medicine and haematology, Oncology and carcinogenesis
Abstract

On August 30, 2017, the U.S. Food and Drug Administration (US-FDA) approved tisagenlecleucel (KYMRIAH, Novartis, Basel, Switzerland), a synthetic bioimmune product of anti-CD19 chimeric antigen receptor-T cells (CAR-T), for the treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). With this new era of personalized cancer immunotherapy, multiple challenges are present ranging from implementation of a CAR-T program to safe delivery of the drug, long-term toxicity monitoring and disease assessments. To address these issues, experts representing the American Society for Blood and Marrow Transplant (ASBMT), the European Group for Blood and Marrow Transplantation (EBMT), the International Society of Cell and Gene Therapy (ISCT), and the Foundation for the Accreditation of Cellular Therapy (FACT), formed a global CAR-T task force to identify and address key questions pertinent for hematologists and transplant physicians regarding the clinical use of anti CD19 CAR-T therapy in patients with B-ALL. This article presents an initial roadmap for navigating common clinical practice scenarios that will become more prevalent now that the first commercially available CAR-T product for B-ALL has been approved.

Published
2019

8. High-dose Alemtuzumab-Cyclosporine vs Tacrolimus-Methotrexate-Sirolimus for Chronic Graft-versus-Host Disease Prevention

Author

Holtzman, Noa G., primary, Curtis, Lauren M, additional, Salit, Rachel B, additional, Shaffer, Brian C, additional, Pirsl, Filip, additional, Ostojic, Alen, additional, Steinberg, Seth M, additional, Schulz, Eduard, additional, Wilder, Jennifer S., additional, Hughes, Thomas E, additional, Rose, Jeremy, additional, Memon, Sarfraz, additional, Korngold, Robert, additional, Gea-Banacloche, Juan, additional, Fowler, Daniel H, additional, Hakim, Frances T, additional, Gress, Ronald E., additional, Bishop, Michael R., additional, and Pavletic, Steven Z, additional

Published
2024
Full Text
View/download PDF

10. Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy

Author

Kansagra, Ankit J, Frey, Noelle V, Bar, Merav, Laetsch, Theodore W, Carpenter, Paul A, Savani, Bipin N, Heslop, Helen E, Bollard, Catherine M, Komanduri, Krishna V, Gastineau, Dennis A, Chabannon, Christian, Perales, Miguel A, Hudecek, Michael, Aljurf, Mahmoud, Andritsos, Leslie, Barrett, John A, Bachanova, Veronika, Bonini, Chiara, Ghobadi, Armin, Gill, Saar I, Hill, Joshua, Kenderian, Saad, Kebriaei, Partow, Nagler, Arnon, Maloney, David, Liu, Hien D, Shah, Nirali N, Kharfan-Dabaja, Mohamed A, Shpall, Elizabeth J, Mufti, Ghulam J, Johnston, Laura, Jacoby, Elad, Bazarbachi, Ali, DiPersio, John F, Pavletic, Steven Z, Porter, David L, Grupp, Stephan A, Sadelain, Michel, Litzow, Mark R, Mohty, Mohamad, and Hashmi, Shahrukh K

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Transplantation, Childhood Leukemia, Pediatric Cancer, Pediatric, Biotechnology, Orphan Drug, Genetics, Pediatric Research Initiative, Cancer, Rare Diseases, Gene Therapy, Immunization, Hematology, Development of treatments and therapeutic interventions, 5.2 Cellular and gene therapies, Good Health and Well Being, Antigens, CD19, Child, Critical Pathways, Drug Approval, Expert Testimony, Humans, Immunotherapy, Adoptive, Practice Patterns, Physicians', Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Receptors, Antigen, T-Cell, Societies, Medical, United States, Young Adult, Chimeric antigen receptor, Leukemia, T cell, Clinical Sciences, Cardiovascular medicine and haematology
Abstract

On August 30, 2017 the US Food and Drug Administration approved tisagenlecleucel (Kymriah; Novartis, Basel, Switzerland), a synthetic bioimmune product of anti-CD19 chimeric antigen receptor T cells (CAR-T), for the treatment of children and young adults with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL). With this new era of personalized cancer immunotherapy, multiple challenges are present, ranging from implementation of a CAR-T program to safe delivery of the drug, long-term toxicity monitoring, and disease assessments. To address these issues experts representing the American Society for Blood and Marrow Transplant, the European Society for Blood and Marrow Transplantation, the International Society of Cell and Gene Therapy, and the Foundation for the Accreditation of Cellular Therapy formed a global CAR-T task force to identify and address key questions pertinent for hematologists and transplant physicians regarding the clinical use of anti CD19 CAR-T therapy in patients with B-ALL. This article presents an initial roadmap for navigating common clinical practice scenarios that will become more prevalent now that the first commercially available CAR-T product for B-ALL has been approved.

Published
2019

11. Toward a Better Understanding of the Atypical Features of Chronic Graft-Versus-Host Disease: A Report from the 2020 National Institutes of Health Consensus Project Task Force

Author

Cuvelier, Geoffrey D.E., Schoettler, Michelle, Buxbaum, Nataliya P., Pinal-Fernandez, Iago, Schmalzing, Marc, Distler, Jörg H.W., Penack, Olaf, Santomasso, Bianca D., Zeiser, Robert, Angstwurm, Klemens, MacDonald, Kelli P.A., Kimberly, W. Taylor, Taylor, Naomi, Bilic, Ervina, Banas, Bernhard, Buettner-Herold, Maike, Sinha, Namita, Greinix, Hildegard T., Pidala, Joseph, Schultz, Kirk R., Williams, Kirsten M., Inamoto, Yoshihiro, Cutler, Corey, Griffith, Linda M., Lee, Stephanie J., Sarantopoulos, Stefanie, Pavletic, Steven Z., and Wolff, Daniel

Published
2022
Full Text
View/download PDF

15. Impaired Bone Mineral Density in Pediatric Patients with Chronic Graft-versus-Host Disease

Author

Buxbaum, Nataliya P, Robinson, Cemre, Sinaii, Ninet, Ling, Alexander, Curtis, Lauren M, Pavletic, Steven Z, Baird, Kristin, and Lodish, Maya B

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Sciences, Stem Cell Research - Nonembryonic - Human, Stem Cell Research, Prevention, Clinical Research, Transplantation, Pediatric, Rare Diseases, Musculoskeletal, Adolescent, Adult, Bone Density, Child, Child, Preschool, Chronic Disease, Female, Graft vs Host Disease, Humans, Male, Risk Factors, Young Adult, cGVHD, Bone mineral density, Vertebral compression fracture, Allogeneic hematopoietic stem, cell transplantation, Allogeneic hematopoietic stem cell transplantation, Immunology, Cardiovascular medicine and haematology
Abstract

Pediatric allogeneic hematopoietic stem cell transplantation (AHSCT) recipients with chronic graft-versus-host disease (cGVHD) are at high risk for endocrinopathies, particularly impaired bone mineral density (BMD). However, rates of BMD impairment in pediatric AHSCT recipients with cGVHD have not been well documented. We report 33 patients with cGVHD who were referred to the National Institutes of Health (NIH) for the Natural History of Clinical and Biological Factors Determining Outcomes in Chronic Graft-versus-Host Disease Study (NCT 0092235) and underwent formal BMD assessment via dual-energy X-ray absorptiometry (DEXA). Not surprisingly, we found much higher rates of BMD impairment than previously reported for pediatric AHSCT recipients who were not stratified by the presence or absence of cGVHD. Most of these patients (73%) had a z-score ≤-2 in at least 1 anatomic site. Although we expected the rate to be higher than that observed for pediatric AHSCT recipients in studies that did not analyze patients with cGVHD separately, this rate is nonetheless extremely high. Furthermore, the overall rate of occult vertebral compression fractures (VCFs) in our cohort was 17%, and the rate was 23% in patients with at least 1 z-score of ≤-2. The rates of BMD impairment and VCF in our pediatric cohort were significantly higher than those seen in the adult AHSCT recipients who were concurrently enrolled on the same study at the NIH and had similar cGVHD severity. We found that older age at cGVHD diagnosis and a greater number of systemic therapies were associated with occult VCF. Moreover, the intensity of current immunosuppression negatively impacted lumbar spine and total hip BMD in this cohort. Our study, although limited by small patient numbers and lack of a control AHSCT recipient group without cGVHD, indicates that children with cGVHD are at a greater risk for BMD impairment than previously appreciated. Given the rising incidence of cGVHD in AHSCT recipients and our findings, we recommend that pre-AHSCT DEXA be incorporated into routine pediatric pretransplantation screening studies. A baseline DEXA study could facilitate longitudinal monitoring of BMD in children, who may be more susceptible than adults to the negative effects of AHSCT on BMD. In addition, given the high risk of BMD impairment in pediatric AHSCT recipients with cGVHD, such patients should undergo BMD evaluation upon developing cGVHD, with continued monitoring thereafter to allow intervention before progression of the BMD impairment to its severe manifestation, VCF.

Published
2018

17. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report

Author

Wolff, Daniel, Radojcic, Vedran, Lafyatis, Robert, Cinar, Resat, Rosenstein, Rachel K., Cowen, Edward W., Cheng, Guang-Shing, Sheshadri, Ajay, Bergeron, Anne, Williams, Kirsten M., Todd, Jamie L., Teshima, Takanori, Cuvelier, Geoffrey D.E., Holler, Ernst, McCurdy, Shannon R., Jenq, Robert R., Hanash, Alan M., Jacobsohn, David, Santomasso, Bianca D., Jain, Sandeep, Ogawa, Yoko, Steven, Philipp, Luo, Zhonghui Katie, Dietrich-Ntoukas, Tina, Saban, Daniel, Bilic, Ervina, Penack, Olaf, Griffith, Linda M., Cowden, Meredith, Martin, Paul J., Greinix, Hildegard T., Sarantopoulos, Stefanie, Socie, Gerard, Blazar, Bruce R., Pidala, Joseph, Kitko, Carrie L., Couriel, Daniel R., Cutler, Corey, Schultz, Kirk R., Pavletic, Steven Z., Lee, Stephanie J., and Paczesny, Sophie

Published
2021
Full Text
View/download PDF

18. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report

Author

DeFilipp, Zachariah, Couriel, Daniel R., Lazaryan, Aleksandr, Bhatt, Vijaya Raj, Buxbaum, Nataliya P., Alousi, Amin M., Olivieri, Attilio, Pulanic, Drazen, Halter, Joerg P., Henderson, Lori A., Zeiser, Robert, Gooley, Ted A., MacDonald, Kelli P.A., Wolff, Daniel, Schultz, Kirk R., Paczesny, Sophie, Inamoto, Yoshihiro, Cutler, Corey S., Kitko, Carrie L., Pidala, Joseph A., Lee, Stephanie J., Socie, Gerard, Sarantopoulos, Stefanie, Pavletic, Steven Z., Martin, Paul J., Blazar, Bruce R., and Greinix, Hildegard T.

Published
2021
Full Text
View/download PDF

19. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report

Author

Kitko, Carrie L., Pidala, Joseph, Schoemans, Hélène M., Lawitschka, Anita, Flowers, Mary E., Cowen, Edward W., Tkaczyk, Eric, Farhadfar, Nosha, Jain, Sandeep, Steven, Philipp, Luo, Zhonghui K., Ogawa, Yoko, Stern, Michael, Yanik, Greg A., Cuvelier, Geoffrey D.E., Cheng, Guang-Shing, Holtan, Shernan G., Schultz, Kirk R., Martin, Paul J., Lee, Stephanie J., Pavletic, Steven Z., Wolff, Daniel, Paczesny, Sophie, Blazar, Bruce R., Sarantopoulos, Stephanie, Socie, Gerard, Greinix, Hildegard, and Cutler, Corey

Published
2021
Full Text
View/download PDF

20. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report

Author

Williams, Kirsten M., Inamoto, Yoshihiro, Im, Annie, Hamilton, Betty, Koreth, John, Arora, Mukta, Pusic, Iskra, Mays, Jacqueline W., Carpenter, Paul A., Luznik, Leo, Reddy, Pavan, Ritz, Jerome, Greinix, Hildegard, Paczesny, Sophie, Blazar, Bruce R., Pidala, Joseph, Cutler, Corey, Wolff, Daniel, Schultz, Kirk R., Pavletic, Steven Z., Lee, Stephanie J., Martin, Paul J., Socie, Gerard, and Sarantopoulos, Stefanie

Published
2021
Full Text
View/download PDF

21. A randomized phase 2 trial of pomalidomide in subjects failing prior therapy for chronic graft-versus-host disease

Author

Curtis, Lauren M., Ostojic, Alen, Venzon, David J., Holtzman, Noa G., Pirsl, Filip, Kuzmina, Zoya J., Baird, Kristin, Rose, Jeremy J., Cowen, Edward W., Mays, Jacqueline W., Mitchell, Sandra A., Parsons-Wandell, Laura, Joe, Galen O., Comis, Leora E., Berger, Ann, Pusic, Iskra, Peer, Cody J., Figg, William D., Cao, Liang, Gale, Robert Peter, Hakim, Frances T., and Pavletic, Steven Z.

Published
2021
Full Text
View/download PDF

23. Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation

Author

Kharfan-Dabaja, Mohamed A, Kumar, Ambuj, Hamadani, Mehdi, Stilgenbauer, Stephan, Ghia, Paolo, Anasetti, Claudio, Dreger, Peter, Montserrat, Emili, Perales, Miguel-Angel, Alyea, Edwin P, Awan, Farrukh T, Ayala, Ernesto, Barrientos, Jacqueline C, Brown, Jennifer R, Castro, Januario E, Furman, Richard R, Gribben, John, Hill, Brian T, Mohty, Mohamad, Moreno, Carol, O'Brien, Susan, Pavletic, Steven Z, Pinilla-Ibarz, Javier, Reddy, Nishitha M, Sorror, Mohamed, Bredeson, Christopher, Carpenter, Paul, and Savani, Bipin N

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Cancer, Transplantation, Hematology, Rare Diseases, Clinical Research, Clinical Trials and Supportive Activities, Lymphoma, Antineoplastic Agents, Child, Child, Preschool, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Practice Guidelines as Topic, Salvage Therapy, Transplantation Conditioning, Transplantation, Homologous, Chronic lymphocytic leukemia, Allogeneic hematopoietic cell transplantation, BCR inhibitors, BCL-2 inhibitors, Clinical Sciences, Immunology, Cardiovascular medicine and haematology
Abstract

We sought to establish clinical practice recommendations to redefine the role of allogeneic hematopoietic cell transplantation (allo-HCT) for patients with chronic lymphocytic leukemia (CLL) in an era of highly active targeted therapies. We performed a systematic review to identify prospective randomized controlled trials comparing allo-HCT against novel therapies for treatment of CLL at various disease stages. In the absence of such data, we invited physicians with expertise in allo-HCT and/or CLL to participate in developing these recommendations. We followed the Grading of Recommendations Assessment, Development and Evaluation methodology. For standard-risk CLL we recommend allo-HCT in the absence of response or if there is evidence of disease progression after B cell receptor (BCR) inhibitors. For high-risk CLL an allo-HCT is recommended after failing 2 lines of therapy and showing an objective response to BCR inhibitors or to a clinical trial. It is also recommended for patients who fail to show an objective response or progress after BCR inhibitors and receive BCL-2 inhibitors, regardless of whether an objective response is achieved. For Richter transformation, we recommend allo-HCT upon demonstration of an objective response to anthracycline-based chemotherapy. A reduced-intensity conditioning regimen is recommended whenever indicated. These recommendations highlight the rapidly changing treatment landscape of CLL. Newer therapies have disrupted prior paradigms, and allo-HCT is now relegated to later stages of relapsed or refractory CLL.

Published
2016

24. Study protocol: Close Assessment and Testing for Chronic Graft-vs.-Host disease (CATCH).

Author

Pidala, Joseph, Carpenter, Paul A., Onstad, Lynn, Pavletic, Steven Z., Hamilton, Betty K., Chen, George L., Farhadfar, Nosha, Hall, Marcie, and Lee, Stephanie J.

Subjects
HEMATOPOIETIC stem cell transplantation, CHRONIC diseases, RESEARCH protocols, GRAFT versus host disease, SKIN biopsy
Abstract

Chronic graft-versus-host disease (GVHD) is an immune-mediated disorder that causes significant late morbidity and mortality following allogeneic hematopoietic cell transplantation. The "Close Assessment and Testing for Chronic GVHD (CATCH)" study is a multi-center Chronic GVHD Consortium prospective, longitudinal cohort study designed to enroll patients before hematopoietic cell transplantation and follow them closely to capture the development of chronic GVHD and to identify clinical and biologic biomarkers of chronic GVHD onset. Data are collected pre-transplant and every two months through one-year post-transplant with chart review thereafter. Evaluations include clinician assessment of chronic GVHD and its manifestations, patient-reported outcomes, multiple biospecimens (blood, saliva, tears, buccal mucosa and fecal samples, biopsies of skin and mouth), laboratory testing, and medical record abstraction. This report describes the rationale, design, and methods of the CATCH study, and invites collaboration with other investigators to leverage this resource. trial registration: This study is registered at www.clinicaltrials.gov as NCT04188912. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Heightened TLR7 Primes BCR-Activated Cells in Chronic Graft-Versus-Host Disease for Effector Functions

Author

Bracken, Sonali J, primary, Suthers, Amy, additional, DiCioccio, Rachel A., additional, Su, Hsuan, additional, Anand, Sarah, additional, Poe, Jonathan C., additional, Jia, Wei, additional, visentin, jonathan, additional, Basher, Fahmin, additional, Jordan, Collin Z, additional, McManigle, William C, additional, Li, Zhiguo, additional, Hakim, Frances T, additional, Pavletic, Steven Z, additional, Bhuiya, Nazmim, additional, Ho, Vincent T., additional, Horwitz, Mitchell E., additional, Chao, Nelson J., additional, and Sarantopoulos, Stefanie, additional

Published
2023
Full Text
View/download PDF

27. Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy

Author

Jain, Tania, Bar, Merav, Kansagra, Ankit J., Chong, Elise A., Hashmi, Shahrukh K., Neelapu, Sattva S., Byrne, Michael, Jacoby, Elad, Lazaryan, Aleksandr, Jacobson, Caron A., Ansell, Stephen M., Awan, Farrukh T., Burns, Linda, Bachanova, Veronika, Bollard, Catherine M., Carpenter, Paul A., DiPersio, John F., Hamadani, Mehdi, Heslop, Helen E., Hill, Joshua A., Komanduri, Krishna V., Kovitz, Craig A., Lazarus, Hillard M., Serrette, Justin M., Mohty, Mohamad, Miklos, David, Nagler, Arnon, Pavletic, Steven Z., Savani, Bipin N., Schuster, Stephen J., Kharfan-Dabaja, Mohamed A., Perales, Miguel-Angel, and Lin, Yi

Published
2019
Full Text
View/download PDF

28. Characterization of Hepatic Dysfunction in Subjects Diagnosed With Chronic GVHD by NIH Consensus Criteria

Author

Yang, Alexander H., Han, Ma Ai Thanda, Samala, Niharika, Rizvi, Bisharah S., Marchalik, Rachel, Etzion, Ohad, Wright, Elizabeth C., Cao, Liang, Hakim, Frances T., Jones, Elizabeth, Kapuria, Devika, Hickstein, Dennis D., Fowler, Daniel, Kanakry, Jennifer A., Kanakry, Christopher G., Kleiner, David E., Koh, Christopher, Pavletic, Steven Z., and Heller, Theo

Published
2022
Full Text
View/download PDF

31. Chronic GvHD NIH Consensus Project Biology Task Force: evolving path to personalized treatment of chronic GvHD

Author

Buxbaum, Nataliya P., primary, Socié, Gerard, additional, Hill, Geoffrey R., additional, MacDonald, Kelli P. A., additional, Tkachev, Victor, additional, Teshima, Takanori, additional, Lee, Stephanie J., additional, Ritz, Jerome, additional, Sarantopoulos, Stefanie, additional, Luznik, Leo, additional, Zeng, Defu, additional, Paczesny, Sophie, additional, Martin, Paul J., additional, Pavletic, Steven Z., additional, Schultz, Kirk R., additional, and Blazar, Bruce R., additional

Published
2023
Full Text
View/download PDF

33. Prospective Phase II Trial of Montelukast to Treat Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation and Investigation into Bronchiolitis Obliterans Syndrome Pathogenesis

Author

Williams, Kirsten M., Pavletic, Steven Z., Lee, Stephanie J., Martin, Paul J., Farthing, Don E., Hakim, Frances T., Rose, Jeremy, Manning-Geist, Beryl L., Gea-Banacloche, Juan C., Comis, Leora E., Cowen, Edward W., Justus, David G., Baird, Kristin, Cheng, Guang-Shing, Avila, Daniele, Steinberg, Seth M., Mitchell, Sandra A., and Gress, Ronald E.

Published
2022
Full Text
View/download PDF

38. An aberrant NOTCH2-BCR signaling axis in B cells from patients with chronic GVHD

Author

Poe, Jonathan C., Jia, Wei, Su, Hsuan, Anand, Sarah, Rose, Jeremy J., Tata, Prasanthi V., Suthers, Amy N., Jones, Corbin D., Kuan, Pei Fen, Vincent, Benjamin G., Serody, Jonathan S., Horwitz, Mitchell E., Ho, Vincent T., Pavletic, Steven Z., Hakim, Frances T., Owzar, Kouros, Zhang, Dadong, Blazar, Bruce R., Siebel, Christian W., Chao, Nelson J., Maillard, Ivan, and Sarantopoulos, Stefanie

Published
2017
Full Text
View/download PDF

40. Single-cell landscape analysis unravels molecular programming of the human B cell compartment in chronic GVHD

Author

Poe, Jonathan C., primary, Fang, Jiyuan, additional, Zhang, Dadong, additional, Lee, Marissa R., additional, DiCioccio, Rachel A., additional, Su, Hsuan, additional, Qin, Xiaodi, additional, Zhang, Jennifer Y., additional, Visentin, Jonathan, additional, Bracken, Sonali J., additional, Ho, Vincent T., additional, Wang, Kathy S., additional, Rose, Jeremy J., additional, Pavletic, Steven Z., additional, Hakim, Frances T., additional, Jia, Wei, additional, Suthers, Amy N., additional, Curry-Chisolm, Itaevia M., additional, Horwitz, Mitchell E., additional, Rizzieri, David A., additional, McManigle, William C., additional, Chao, Nelson J., additional, Cardones, Adela R., additional, Xie, Jichun, additional, Owzar, Kouros, additional, and Sarantopoulos, Stefanie, additional

Published
2023
Full Text
View/download PDF

43. Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation

Author

Kharfan-Dabaja, Mohamed A., Kumar, Ambuj, Hamadani, Mehdi, Stilgenbauer, Stephan, Ghia, Paolo, Anasetti, Claudio, Dreger, Peter, Montserrat, Emili, Perales, Miguel-Angel, Alyea, Edwin P., Awan, Farrukh T., Ayala, Ernesto, Barrientos, Jacqueline C., Brown, Jennifer R., Castro, Januario E., Furman, Richard R., Gribben, John, Hill, Brian T., Mohty, Mohamad, Moreno, Carol, O'Brien, Susan, Pavletic, Steven Z., Pinilla-Ibarz, Javier, Reddy, Nishitha M., Sorror, Mohamed, Bredeson, Christopher, Carpenter, Paul, and Savani, Bipin N.

Published
2016
Full Text
View/download PDF

44. Characterization and Risk Factor Analysis of Osteoporosis in a Large Cohort of Patients with Chronic Graft-versus-Host Disease

Author

Pirsl, Filip, Curtis, Lauren M., Steinberg, Seth M., Tella, Sri Harsha, Katić, Mašenjka, Dobbin, Marnie, Hsu, Jennifer, Hakim, Fran T., Mays, Jacqueline W., Im, Annie P., Pulanić, Dražen, Mitchell, Sandra A., Baruffaldi, Judy, Masuch, Licia, Halverson, David C., Gress, Ronald E., Barsony, Julianna, and Pavletic, Steven Z.

Published
2016
Full Text
View/download PDF

45. Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation

Author

Williams, Kirsten M., Cheng, Guang-Shing, Pusic, Iskra, Jagasia, Madan, Burns, Linda, Ho, Vincent T., Pidala, Joseph, Palmer, Jeanne, Johnston, Laura, Mayer, Sebastian, Chien, Jason W., Jacobsohn, David A., Pavletic, Steven Z., Martin, Paul J., Storer, Barry E., Inamoto, Yoshihiro, Chai, Xiaoyu, Flowers, Mary E.D., and Lee, Stephanie J.

Published
2016
Full Text
View/download PDF

47. The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen

Author

Urbano-Ispizua, Alvaro, Pavletic, Steven Z., Flowers, Mary E., Klein, John P., Zhang, Mei-Jie, Carreras, Jeanette, Montoto, Silvia, Perales, Miguel-Angel, Aljurf, Mahmoud D., Akpek, Görgün, Bredeson, Christopher N., Costa, Luciano J., Dandoy, Christopher, Freytes, César O., Fung, Henry C., Gale, Robert Peter, Gibson, John, Hamadani, Mehdi, Hayashi, Robert J., Inamoto, Yoshihiro, Inwards, David J., Lazarus, Hillard M., Maloney, David G., Martino, Rodrigo, Munker, Reinhold, Nishihori, Taiga, Olsson, Richard F., Rizzieri, David A., Reshef, Ran, Saad, Ayman, Savani, Bipin N., Schouten, Harry C., Smith, Sonali M., Socié, Gérard, Wirk, Baldeep, Yu, Lolie C., and Saber, Wael

Published
2015
Full Text
View/download PDF

49. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report

Author

Carpenter, Paul A., Kitko, Carrie L., Elad, Sharon, Flowers, Mary E.D., Gea-Banacloche, Juan C., Halter, Jörg P., Hoodin, Flora, Johnston, Laura, Lawitschka, Anita, McDonald, George B., Opipari, Anthony W., Savani, Bipin N., Schultz, Kirk R., Smith, Sean R., Syrjala, Karen L., Treister, Nathaniel, Vogelsang, Georgia B., Williams, Kirsten M., Pavletic, Steven Z., Martin, Paul J., Lee, Stephanie J., and Couriel, Daniel R.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results